Matthew Cox

Title: Matthew Cox - Innovator in Antibody Research

Introduction

Matthew Cox is a prominent inventor based in Slough, GB. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of neutralising antibodies. His work focuses on addressing major exotoxins that pose health risks.

Latest Patents

Matthew Cox holds a patent for "Neutralising antibodies to the major exotoxins TcdA and TcdB." This invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins, TcdA and TcdB. The patent also highlights novel neutralisation and antigen binding properties of individual monoclonal antibodies and mixtures thereof. He has 1 patent to his name.

Career Highlights

Matthew Cox is associated with UCB Biopharma Sprl, a company known for its innovative approaches in biopharmaceutical development. His work at UCB Biopharma has positioned him as a key player in the research and development of therapeutic solutions.

Collaborations

Matthew has collaborated with notable colleagues, including David Paul Humphreys and Daniel John Lightwood. These collaborations have further enhanced the impact of his research in the field.

Conclusion

Matthew Cox is a dedicated inventor whose work in neutralising antibodies has the potential to make significant advancements in biopharmaceuticals. His contributions are vital in the ongoing fight against harmful exotoxins.